← All trials
NCT05768880
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 5, 2023
- Primary completion
- Jan 15, 2028
- Completion date
- Dec 31, 2043
- First posted
- Mar 15, 2023
- Last posted
- Jun 29, 2023
- Enrollment
- 72
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- University of WashingtonLead sponsor
- University of WashingtonOverall official - principal investigator
- University of WashingtonReponsible party - principal investigator
- University of WashingtonStudy chair
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.